N
Nicolas F. Delahaye
Researcher at Institut Gustave Roussy
Publications - 13
Citations - 2072
Nicolas F. Delahaye is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Immunogenic cell death & IκB kinase. The author has an hindex of 13, co-authored 13 publications receiving 1898 citations. Previous affiliations of Nicolas F. Delahaye include University of Paris-Sud & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.
Yuting Ma,Laetitia Aymeric,Clara Locher,Stephen R. Mattarollo,Nicolas F. Delahaye,Pablo Pereira,Laurent Boucontet,Lionel Apetoh,François Ghiringhelli,Noelia Casares,Juan José Lasarte,Goro Matsuzaki,Koichi Ikuta,Bernard Ryffel,Kamel Benlagha,Antoine Tesniere,Nicolas Ibrahim,Julie Déchanet-Merville,Nathalie Chaput,Mark J. Smyth,Guido Kroemer,Laurence Zitvogel +21 more
TL;DR: IL-17 production by γδ T cells is required for tumor cell infiltration by IFN-γ–producing CD8+ T cells and inhibition of tumor growth in response to anthracyclines.
Journal ArticleDOI
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
Nicolas F. Delahaye,Sylvie Rusakiewicz,Sylvie Rusakiewicz,Isabelle Martins,Cédric Ménard,Cédric Ménard,Stephan Roux,Stephan Roux,Luc Lyonnet,Pascale Paul,Matthieu Sarabi,Matthieu Sarabi,Nathalie Chaput,Nathalie Chaput,Michaela Semeraro,Michaela Semeraro,Véronique Minard-Colin,Véronique Minard-Colin,Vichnou Poirier-Colame,Kariman Chaba,Kariman Chaba,Caroline Flament,Caroline Flament,Véronique Baud,Véronique Baud,Véronique Baud,Hélène Authier,Hélène Authier,Hélène Authier,Saadia Kerdine-Römer,Marc Pallardy,Isabelle Cremer,Isabelle Cremer,Laetitia Peaudecerf,Benedita Rocha,Dominique Valteau-Couanet,Dominique Valteau-Couanet,Javier Celis Gutierrez,Jacques A. Nunès,Frédéric Commo,Frédéric Commo,Sylvie Bonvalot,Nicolas Ibrahim,Philippe Terrier,Paule Opolon,Paule Opolon,Cristina Bottino,Cristina Bottino,Alessandro Moretta,Jan Tavernier,Pascal Rihet,Jean Michel Coindre,Jean-Yves Blay,Nicolas Isambert,Jean Franãois Emile,Eric Vivier,A. Lecesne,Guido Kroemer,Laurence Zitvogel +58 more
TL;DR: The genetically determined NKp30 status predicts the clinical outcomes of individuals with GIST independently from KIT mutation, and predominant expression of the immunosuppressiveNKp30c isoform was associated with reduced survival of subjects.
Journal ArticleDOI
The IKK complex contributes to the induction of autophagy
Alfredo Criollo,Laura Senovilla,Laura Senovilla,Laura Senovilla,Hélène Authier,Maria Chiara Maiuri,Eugenia Morselli,Eugenia Morselli,Eugenia Morselli,Ilio Vitale,Ilio Vitale,Ilio Vitale,Oliver Kepp,Oliver Kepp,Oliver Kepp,Ezgi Tasdemir,Ezgi Tasdemir,Ezgi Tasdemir,Lorenzo Galluzzi,Lorenzo Galluzzi,Lorenzo Galluzzi,Shensi Shen,Shensi Shen,Shensi Shen,Maximilien Tailler,Maximilien Tailler,Maximilien Tailler,Nicolas F. Delahaye,Nicolas F. Delahaye,Nicolas F. Delahaye,Antoine Tesniere,Antoine Tesniere,Antoine Tesniere,Daniela De Stefano,Amena Ben Younes,Amena Ben Younes,Amena Ben Younes,Francis Harper,Gérard Pierron,Sergio Lavandero,Laurence Zitvogel,Laurence Zitvogel,Laurence Zitvogel,Alain Israël,Véronique Baud,Guido Kroemer,Guido Kroemer,Guido Kroemer +47 more
TL;DR: It is shown that multiple inducers of autophagy, including nutrient depletion, trigger the activation of the IKK (IκB kinase) complex that is best known for its essential role in theactivation of the transcription factor NF‐κB by stress.
Journal ArticleDOI
IL-18 induces PD-1-dependent immunosuppression in cancer.
Magali Terme,Evelyn Ullrich,Laetitia Aymeric,Kathrin Meinhardt,Mélanie Desbois,Nicolas F. Delahaye,Sophie Viaud,Bernhard Ryffel,Hideo Yagita,Gilles Kaplanski,Armelle Prévost-Blondel,Masashi Kato,Joachim L. Schultze,Eric Tartour,Guido Kroemer,Nathalie Chaput,Laurence Zitvogel +16 more
TL;DR: IL-18 is defined as an immunosuppressive cytokine in cancer because it promotes the development of NK-controlled metastases in a PD-1-dependent manner and novel clinical implementations of anti-PD-1 antibodies in human malignancies that produce IL-18 are suggested.
Journal ArticleDOI
Natural killer cell-directed therapies: moving from unexpected results to successful strategies.
TL;DR: Deeper investigation into the benefits of combination therapy, greater understanding of the functional distinctions between NK cell subsets, and design of new tools to monitor NK cell activity are needed to strengthen the ability to harness the power of NK cells for therapeutic aims.